Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
GO:009872714 | Esophagus | ESCC | maintenance of cell number | 90/8552 | 134/18723 | 3.94e-07 | 5.43e-06 | 90 |
GO:001982714 | Esophagus | ESCC | stem cell population maintenance | 88/8552 | 131/18723 | 5.23e-07 | 6.97e-06 | 88 |
GO:00063673 | Esophagus | ESCC | transcription initiation from RNA polymerase II promoter | 56/8552 | 77/18723 | 1.30e-06 | 1.59e-05 | 56 |
GO:000635211 | Esophagus | ESCC | DNA-templated transcription, initiation | 86/8552 | 130/18723 | 1.88e-06 | 2.19e-05 | 86 |
GO:00708973 | Esophagus | ESCC | transcription preinitiation complex assembly | 30/8552 | 36/18723 | 3.60e-06 | 3.95e-05 | 30 |
GO:00439662 | Esophagus | ESCC | histone H3 acetylation | 43/8552 | 61/18723 | 7.57e-05 | 5.67e-04 | 43 |
GO:00511232 | Esophagus | ESCC | RNA polymerase II preinitiation complex assembly | 18/8552 | 24/18723 | 3.43e-03 | 1.41e-02 | 18 |
GO:20000361 | Esophagus | ESCC | regulation of stem cell population maintenance | 23/8552 | 33/18723 | 4.57e-03 | 1.78e-02 | 23 |
GO:0006367 | Liver | Cirrhotic | transcription initiation from RNA polymerase II promoter | 31/4634 | 77/18723 | 1.91e-03 | 1.20e-02 | 31 |
GO:0070897 | Liver | Cirrhotic | transcription preinitiation complex assembly | 17/4634 | 36/18723 | 2.82e-03 | 1.63e-02 | 17 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TAF6 | SNV | Missense_Mutation | novel | c.2118C>A | p.Asn706Lys | p.N706K | P49848 | protein_coding | tolerated_low_confidence(0.3) | benign(0) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
TAF6 | SNV | Missense_Mutation | | c.1226N>T | p.Thr409Ile | p.T409I | P49848 | protein_coding | deleterious(0.02) | possibly_damaging(0.505) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
TAF6 | SNV | Missense_Mutation | novel | c.960N>T | p.Met320Ile | p.M320I | P49848 | protein_coding | tolerated(0.05) | benign(0.177) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
TAF6 | SNV | Missense_Mutation | novel | c.593N>T | p.Ala198Val | p.A198V | P49848 | protein_coding | tolerated(0.15) | benign(0.035) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
TAF6 | insertion | Frame_Shift_Ins | novel | c.298_299insTACAAGGAGATCACCGAGGCCTGCGTGGGCT | p.Arg100LeufsTer18 | p.R100Lfs*18 | P49848 | protein_coding | | | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
TAF6 | SNV | Missense_Mutation | | c.871N>G | p.Gln291Glu | p.Q291E | P49848 | protein_coding | tolerated(0.49) | benign(0.113) | TCGA-C5-A1BL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TAF6 | SNV | Missense_Mutation | novel | c.1340N>A | p.Pro447His | p.P447H | P49848 | protein_coding | deleterious(0.01) | possibly_damaging(0.74) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TAF6 | SNV | Missense_Mutation | rs766556536 | c.1427N>A | p.Arg476His | p.R476H | P49848 | protein_coding | tolerated(0.12) | benign(0.187) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
TAF6 | SNV | Missense_Mutation | | c.1038N>T | p.Met346Ile | p.M346I | P49848 | protein_coding | tolerated(0.79) | benign(0.023) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
TAF6 | SNV | Missense_Mutation | | c.557N>T | p.Pro186Leu | p.P186L | P49848 | protein_coding | deleterious(0.03) | probably_damaging(0.987) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |